Brokerages Set ICON Public Limited (NASDAQ:ICLR) PT at $279.17

ICON Public Limited (NASDAQ:ICLR) has been assigned a consensus rating of “Moderate Buy” from the fifteen analysts that are currently covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation, eleven have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $279.17.

Several research analysts have recently issued reports on ICLR shares. Citigroup lowered their price objective on ICON Public from $300.00 to $290.00 and set a “buy” rating for the company in a research report on Monday, January 6th. Robert W. Baird lowered their price objective on ICON Public from $221.00 to $203.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $263.00 price objective on shares of ICON Public in a research report on Wednesday, January 15th. Barclays lowered their price objective on ICON Public from $275.00 to $240.00 and set an “overweight” rating for the company in a research report on Friday, February 21st. Finally, Truist Financial lowered their price objective on ICON Public from $284.00 to $262.00 and set a “buy” rating for the company in a research report on Thursday, February 13th.

ICON Public Trading Down 0.3 %

ICLR opened at $183.96 on Tuesday. ICON Public has a 12 month low of $174.93 and a 12 month high of $347.72. The stock has a market capitalization of $14.86 billion, a price-to-earnings ratio of 19.30, a PEG ratio of 1.86 and a beta of 1.21. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.26 and a quick ratio of 1.34. The business has a fifty day moving average price of $193.43 and a 200 day moving average price of $227.86.

ICON Public (NASDAQ:ICLR) last released its earnings results on Wednesday, February 19th. The medical research company reported $3.42 EPS for the quarter, topping the consensus estimate of $3.41 by $0.01. The firm had revenue of $2.04 billion during the quarter, compared to analysts’ expectations of $2.04 billion. ICON Public had a return on equity of 11.81% and a net margin of 9.56%. Sell-side analysts expect that ICON Public will post 13.38 earnings per share for the current fiscal year.

Institutional Trading of ICON Public

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Sierra Ocean LLC purchased a new stake in ICON Public during the 4th quarter valued at approximately $29,000. Park Place Capital Corp raised its stake in ICON Public by 281.4% during the 4th quarter. Park Place Capital Corp now owns 225 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 166 shares during the last quarter. Private Trust Co. NA raised its stake in ICON Public by 48.8% during the 4th quarter. Private Trust Co. NA now owns 250 shares of the medical research company’s stock valued at $52,000 after acquiring an additional 82 shares during the last quarter. GAMMA Investing LLC raised its stake in ICON Public by 64.0% during the 4th quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock valued at $91,000 after acquiring an additional 169 shares during the last quarter. Finally, First Horizon Advisors Inc. raised its stake in ICON Public by 33.9% during the 3rd quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock valued at $172,000 after acquiring an additional 151 shares during the last quarter. 95.61% of the stock is owned by hedge funds and other institutional investors.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.